FDA veteran Dunn to join Prothena’s board
Plus: Lucera named CFO at Editas, and updates from Erasca, Sangamo, AlloVir and more
Prothena Corp. plc (NASDAQ:PRTA) appointed Billy Dunn, former director of FDA’s Office of Neuroscience, to its board. An 18-year veteran of the agency, Dunn was a strident advocate for regulatory flexibility and perhaps best remembered for his role in the controversial accelerated approval of Alzheimer’s disease therapy Aduhelm aducanumab-avwa. Prothena recently reported preclinical data for anti-amyloid mAb PRX012 to treat the disease.
Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) hired Erick Lucera as EVP and CFO, effective May 17. Lucera succeeds Michelle Robertson, who is stepping down to pursue external opportunities, and will remain with the company in an advisory role until Aug. 16. Lucera was CFO at Aveo Pharmaceuticals Inc., which was acquired by LG Chem Ltd. (KSE:051910)...